Hetero Labs filed an application with the Central Drugs Standard Control Organisation (CDSCO) last week. The CDSCO may soon reach out to ICMR for suggestions.
In science, establishing that something doesn’t work is as crucial as finding a solution. This is why most Covid-19 clinical trials are repurposing existing drugs.
Cipla, Hetero Labs, Jubilant Lifesciences & Mylan have now been allowed by remdesivir’s patent holder, Gilead, to produce the drug that has shown promise in Covid-19 treatment.
Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the manufacturing process to scale up remdesivir production.
Drug has shown benefits in reducing recovery time for some patients, and the govt has asked companies if they’re in touch with Gilead Sciences for a licence.
Gilead Sciences plans a global consortium of pharma firms for production. It says decision of partnership will depend on how fast the drug’s supply can be ramped up.
Once seen as a fading presence on India’s investment & startup picture, the state is slowly moving up the ladder, with policy reforms & infrastructure building.
Agreement signed during 17th Joint Working Group (JWG) on defence cooperation. Defence Secretary Rajesh Kumar Singh met Director General in Israeli Ministry of Defence Amir Baram Tuesday.
This world is being restructured and redrawn by one man, and what’s his power? It’s not his formidable military. It’s trade. With China, it turned on him.
Hii I need a remdesivir 100 mg I.v